224 related articles for article (PubMed ID: 10194593)
1. The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
Nutting C; Folkes A
Clin Oncol (R Coll Radiol); 1999; 11(1):66. PubMed ID: 10194593
[No Abstract] [Full Text] [Related]
2. [Raltitrexed in colorectal cancer].
Comandone A; Oliva C; Dal Canton O; Boglione A; Bergnolo P
Tumori; 2001; 87(1 Suppl 1):S53-4. PubMed ID: 11300026
[No Abstract] [Full Text] [Related]
3. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials referral resource. Clinical trials with tomudex.
Sorensen JM; Cheson BD; Phillips PH
Oncology (Williston Park); 1996 Jul; 10(7):1041-2. PubMed ID: 8837120
[No Abstract] [Full Text] [Related]
5. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
Avallone A; Di Gennaro E; Silvestro L; Iaffaioli VR; Budillon A
Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance in colon cancer.
Gorlick R; Bertino JR
Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
Sato A; Kurihara M; Horikoshi N; Aiba K; Kikkawa N; Shirouzu K; Mitachi Y; Sakata Y; Wakui A
Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
[TBL] [Abstract][Full Text] [Related]
8. Raltitrexed in colorectal cancer.
Drug Ther Bull; 1996 Oct; 34(10):78-80. PubMed ID: 8936802
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
Wilson KS; Fitzgerald CA; Barnett JB; Gill S; Khoo KE
Cancer Invest; 2007 Dec; 25(8):711-4. PubMed ID: 18058467
[TBL] [Abstract][Full Text] [Related]
10. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
Köhne CH; Thuss-Patience P; Friedrich M; Daniel PT; Kretzschmar A; Benter T; Bauer B; Dietz R; Dörken B
Br J Cancer; 1998 Mar; 77(6):973-7. PubMed ID: 9528843
[TBL] [Abstract][Full Text] [Related]
11. Raltitrexed, a novel folate-based thymidylate synthase inhibitor, for the treatment of acute leukemia: is this drug active against acute myelogenous leukemia?
Takemura Y; Kobayashi H; Miyachi H
Int J Hematol; 2000 Jul; 72(1):112-4. PubMed ID: 10979221
[No Abstract] [Full Text] [Related]
12. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.
Kempin S; Gutierrez J; Wilson E; Lowery C; Diasio R
Cancer Invest; 2002; 20(7-8):992-5. PubMed ID: 12449732
[TBL] [Abstract][Full Text] [Related]
13. New drugs in therapy of colorectal cancer: preclinical studies.
Rustum YM; Cao S
Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
[TBL] [Abstract][Full Text] [Related]
14. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Gunasekara NS; Faulds D
Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.
Decoster L; Neyns B; Akouaouach H; Fontaine C; Schallier D; De Grève JL
Anticancer Res; 2004; 24(3b):2037-40. PubMed ID: 15274397
[TBL] [Abstract][Full Text] [Related]
16. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
Grem JL; Sorensen JM; Cullen E; Takimoto CH; Steinberg SM; Chen AP; Hamilton JM; Arbuck SG; McAtee N; Lawrence D; Goldspiel B; Johnston PG; Allegra CJ
Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
[TBL] [Abstract][Full Text] [Related]
17. Talking 'Tomudex': introduction.
Sobrero A
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S1-3. PubMed ID: 9376631
[No Abstract] [Full Text] [Related]
18. Raltitrexed: optimism and reality.
Wilson KS; Malfair Taylor SC
Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1447-54. PubMed ID: 19863453
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase inhibition, a dead end?
Herrmann R
Eur J Cancer; 1995 Nov; 31A(12):1919-20. PubMed ID: 8562141
[No Abstract] [Full Text] [Related]
20. Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed).
Cunningham D
Tumori; 1997; 83(1 Suppl):S70-1. PubMed ID: 9154074
[No Abstract] [Full Text] [Related]
[Next] [New Search]